全文获取类型
收费全文 | 63240篇 |
免费 | 6408篇 |
国内免费 | 111篇 |
专业分类
耳鼻咽喉 | 743篇 |
儿科学 | 1800篇 |
妇产科学 | 1771篇 |
基础医学 | 9673篇 |
口腔科学 | 1397篇 |
临床医学 | 8172篇 |
内科学 | 11997篇 |
皮肤病学 | 917篇 |
神经病学 | 5541篇 |
特种医学 | 2114篇 |
外国民族医学 | 1篇 |
外科学 | 7730篇 |
综合类 | 1068篇 |
现状与发展 | 1篇 |
一般理论 | 48篇 |
预防医学 | 6658篇 |
眼科学 | 964篇 |
药学 | 5054篇 |
中国医学 | 117篇 |
肿瘤学 | 3993篇 |
出版年
2023年 | 417篇 |
2022年 | 669篇 |
2021年 | 1282篇 |
2020年 | 863篇 |
2019年 | 1423篇 |
2018年 | 1508篇 |
2017年 | 1147篇 |
2016年 | 1272篇 |
2015年 | 1357篇 |
2014年 | 1826篇 |
2013年 | 2593篇 |
2012年 | 3719篇 |
2011年 | 3705篇 |
2010年 | 2008篇 |
2009年 | 1827篇 |
2008年 | 3083篇 |
2007年 | 3167篇 |
2006年 | 2920篇 |
2005年 | 2946篇 |
2004年 | 2719篇 |
2003年 | 2541篇 |
2002年 | 2529篇 |
2001年 | 1682篇 |
2000年 | 1652篇 |
1999年 | 1475篇 |
1998年 | 757篇 |
1997年 | 639篇 |
1996年 | 510篇 |
1995年 | 549篇 |
1994年 | 507篇 |
1993年 | 467篇 |
1992年 | 1158篇 |
1991年 | 1083篇 |
1990年 | 1071篇 |
1989年 | 980篇 |
1988年 | 913篇 |
1987年 | 941篇 |
1986年 | 898篇 |
1985年 | 913篇 |
1984年 | 723篇 |
1983年 | 619篇 |
1982年 | 459篇 |
1981年 | 369篇 |
1980年 | 373篇 |
1979年 | 590篇 |
1978年 | 449篇 |
1977年 | 373篇 |
1976年 | 375篇 |
1974年 | 383篇 |
1972年 | 344篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献4.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
5.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
6.
7.
8.
9.
10.